The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.
Onyema Ogbuagu, MBBCh, FACP, FIDSA
Advertisement
Articles by Onyema Ogbuagu, MBBCh, FACP, FIDSA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Withdrawal of Aid Could Cause Millions of Lives Lost to HIV
2
EASO Recommends Semaglutide, Tirzepatide for First-Line Obesity Therapy
3
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
4
FDA Approves Second Generic Mifepristone Pill for Abortion
5
